Real‐world outcomes of addition of insulin glargine 300 U/ mL (Gla‐300) to GLP ‐1 RA therapy in people with type 2 diabetes: The DELIVER‐G study

In people with type 2 diabetes mellitus (PWD2) suboptimally controlled with GLP-1 receptor agonist (GLP-1 RA) therapy, addition of basal insulin (BI) is recommended. However, real-world data on the addition of BI to GLP-1 RA therapy are limited.We used a US electronic medical record data source (IBM® Explorys®) of approximately 4 million PWD2 to assess the real-world impact of adding the second-generation BI analogue insulin glargine 300 U/mL (Gla-300) to GLP-1 RA therapy. Insulin-naïve PWD2 receiving GLP-1 RAs who also received Gla-300 between 1 March 2015 and 30 September 2019 were identified; participants were required to have data for ≥12 months before, and ≥6 months after, addition of Gla-300.Mean age of participants (N=271) was 57.9 (SD: 10.8) years. Baseline HbA1c was 9.16% and was significantly reduced (-0.97 [SD: 1.60], P<0.0001) after addition of Gla-300; a significant increase in the proportion of PWD2 achieving HbA1c control was observed after addition of Gla-300 (HbA1c <7.0%: 4.80% vs. 22.14%, P<0.0001; HbA1c <8.0%: 19.56% vs. 51.29%, P<0.0001). Incidence of overall (8.49% vs. 9.59%, P=0.513) and inpatient/emergency department (ED)-associated hypoglycaemia (0.37% vs. 0.74%, P=1.000), as well as overall (0.33 vs. 0.46 PPPY, P=0.170) and inpatient/ED-associated hypoglycaemia events (0.01 vs. 0.04 PPPY, P=0.466) were similar before and after addition of Gla-300.In US real-world clinical practice, adding Gla-300 to GLP-1 RA significantly improved glycaemic control without significantly increasing hypoglycaemia in PWD2. Further research into the effect of adding Gla-300 to GLP-1 RA therapy is warranted. This article is protected by copyright. All rights reserved.